ONGLYZA

The mark consists of the word "ONGLYZA" and a sunburst design originating from the letter "L".

US serial number:85162195
Application filling date:Oct. 27, 2010
Register:Principal
Mark type:Trademark
Status:Registered. The registration date is used to determine when post-registration maintenance documents are due.
Status date:May 31, 2011
Publication date:Mar. 15, 2011
Standard character claim:No
Mark drawing type:3 - AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/ LETTER(S)/NUMBER(S)
Goods and services:For: Printed matter, namely, brochures and pamphlets on the subject of diabetes International Class(es): 016- Primary Class U.S Class(es): 002,005,022,023,029,037,038,050 Class Status: ACTIVE Basis: 1(a) First Use: Oct. 19, 2009 Use in Commerce: Oct. 19,
Services:Printed matter namely brochures and pamphlets on the subject of diabetes
Current owner owner name:ASTRAZENECA AB
Current owner owner address:VASTRA MALAREHAMNEN 9 SODERTALJE SWEDEN SE-151 85
Current owner legal entity type:COMPANY
Current owner state or country:SWEDEN
Attorney name:Marc Stanislawczyk
Attorney email:trademarks@astrazeneca.com
Attorney docket number:BMS227/US
Attorney email authorized:Yes
Correspondent name address:Marc Stanislawczyk AstraZeneca Pharmaceuticals LLP 1800 Concord Pike FOP3-022 Wilmington, DELAWARE UNITED STATES 19850-5437
Correspondent phone:302.885.0133
Correspondent email:trademarks@astrazeneca.com Marc.Stanislawczyk@astrazeneca.com paula.wright@astrazeneca.com
Correspondent fax:302.886.4693
Correspondent email authorized ONGLYZA:Yes

Reviews

Required fields are marked *